Clinical Observation on Right-Supporting Liver-Emolliating Formula Combined With Lamivudine for 30 Cases of Liver Fibrosis in Chronic Hepatitis B

LIU Junhong; WANG Longde; WANG Min; MAO Lanfang

doi:10.13288/j.11-2166/r.2014.15.013

您当前的位置：

首页 >

文章列表页 >

Clinical Observation on Right-Supporting Liver-Emolliating Formula Combined With Lamivudine for 30 Cases of Liver Fibrosis in Chronic Hepatitis B

更新时间：2021-11-17

- Clinical Observation on Right-Supporting Liver-Emolliating Formula Combined With Lamivudine for 30 Cases of Liver Fibrosis in Chronic Hepatitis B
- Journal of Traditional Chinese Medicine Vol. 55, Issue 15, Pages: 1307-1310(2014)
- 作者机构：
  
  1. 甘肃中医学院附属医院
  2. 贵阳中医学院第一附属医院
  3. 甘肃中医学院
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2014.15.013
  CLC： R512.62;R575.2
- Published：2014
- 稿件说明：
移动端阅览
[1]刘俊宏,汪龙德,王敏,毛兰芳.扶正柔肝方联合拉米夫定片治疗慢性乙型肝炎肝纤维化30例临床观察[J].中医杂志,2014,55(15):1307-1310.

LIU Junhong, WANG Longde, WANG Min, et al. Clinical Observation on Right-Supporting Liver-Emolliating Formula Combined With Lamivudine for 30 Cases of Liver Fibrosis in Chronic Hepatitis B[J]. Journal of Traditional Chinese Medicine2014, 55(15): 1307-1310.
[1]刘俊宏,汪龙德,王敏,毛兰芳.扶正柔肝方联合拉米夫定片治疗慢性乙型肝炎肝纤维化30例临床观察[J].中医杂志,2014,55(15):1307-1310. DOI： 10.13288/j.11-2166/r.2014.15.013.

LIU Junhong, WANG Longde, WANG Min, et al. Clinical Observation on Right-Supporting Liver-Emolliating Formula Combined With Lamivudine for 30 Cases of Liver Fibrosis in Chronic Hepatitis B[J]. Journal of Traditional Chinese Medicine2014, 55(15): 1307-1310. DOI： 10.13288/j.11-2166/r.2014.15.013.

摘要

目的观察扶正柔肝方联合拉米夫定片治疗慢性乙型肝炎肝纤维化的临床疗效。方法将60例患者随机分为治疗组和对照组各30例。两组患者均口服拉米夫定片

每次100mg

每日1次。治疗组加用扶正柔肝方

每日1剂

早晚温服。对照组加用大黄虫胶囊治疗

每次1.6g口服

每日两次。两组均以8周为1个疗程

共治疗6个疗程。治疗前后分别观察两组中医证候积分、肝功能指标[包括丙氨酸氨基转移酶（ALT）、门冬氨酸氨基转移酶（AST）、总胆红素（TBiL）、血清白蛋白（ALB）]、血清肝纤维化指标[包括透明质酸（HA）、IV型胶原（Ⅳ-C）、Ⅲ型前胶原（PCⅢ）和层黏蛋白（LN）]、AST与血小板计数比值指数（APRI）与ALT/AST/血小板指数（TPRI）

彩色多普勒超声仪检测门静脉内径、脾静脉内径及脾脏厚度。结果治疗组临床疗效总有效率为93.33%

对照组为70.00%

治疗组明显高于对照组（P<0.05）。两组患者治疗后与治疗前比较

中医证候积分、门静脉内径、脾静脉内径、脾脏厚度、肝功能及肝纤维化标志物检测结果均明显降低（P<0.05或P<0.01）

并且治疗组均低于对照组（P<0.05或P<0.01）。结论扶正柔肝方联合拉米夫定片治疗慢性乙型肝炎肝纤维化疗效确切

可明显改善临床症状

减轻肝脏损伤。

Abstract

Objective To observe the efficacy of Right-Supporting Liver-Emolliating Formula for liver fibrosis in chronic hepatitis B. Methods Sixty patients were randomized into the treatment group and control group

with 30in each. The patients in both groups were orally taken Lamivudine Tablets（100mg /each time

once daily）. The treatment group was added with Right-Supporting Liver-Emolliating Formula one dose daily. The control group was added with Dahuang Zhechong Capsules（1. 6 g /each time

twice daily）. One treatment course lasted for 8 weeks and the treatment lasted for 6 courses. The TCM syndrome scores

alanine aminotransferase（ALT）

aspartate aminotransferase（AST）

total bilirubin（TBil）

albumin（ALB）

hyaluronic acid（ HA）

IV-collagen（ IV-C）

procollagen-Ⅲ（PC-Ⅲ）

laminin（LN）

AST to platelet ratio index（APRI） and ALT/AST/platelet ratio index（TPRI） were observed before and after treatment. The portal vein diameter

splenic vein diameter and thickness of spleen were detected by color Doppler ultrasound. Results The total effective rate of the treatment group and control group was93. 33% and 70. 00% respectively

with a significant difference between groups（ P < 0. 05）. The TCM syndrome scores

indicators of color Doppler ultrasound（except the control group）

liver function（except ALB in the control group） and markers of liver fibrosis in both groups were significantly decreased after treatment（ P < 0. 05 or P <0. 01）

especially in the treatment group（ P < 0. 05 or P < 0. 01）. Conclusion Right-Supporting LiverEmolliating Formula is effective for liver fibrosis in chronic hepatitis B and can improve symptoms and reduce liver injury.

关键词

Keywords

references

查看原文

Views

276

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical Observation on Telbivudine Tablets Combined with Dangfei Liganning Capsule（当飞利肝宁胶囊） in the Treatment of 30 Cases of Chronic Hepatitis B with HBeAg Positive

Effect of Yinqi Sanhuang Jiedu Decoction （茵芪三黄解毒汤） on Macrophage Polarization and the Piezo1/PI3K/AKT Pathway in Liver Tissue of Liver Fibrosis Model Mice

Pathogenesis Characteristics and Progression Patterns of Liver Fibrosis in 644 Patients with Chronic Hepatitis B

The Effect of Fuzheng Huaji Formula （扶正化积方） for Chronic Hepatitis B on Reduction of the Incidence of Liver Cirrhosis and Hepatocellular Carcinoma：A Retrospective Cohort Study

Evolutionary Law of Syndrome and Syndrome Elements during the Malignant Transformation of Chronic Hepatitis B

Related Author

SHEN Jianjun

HUANG Bohao

WU Qingjuan

WANG Jiuchong

LI Yanbo

LEI Chao

LYU Wenliang

CHEN Bowu

Related Institution

The Second Affiliated Hospital of Southeast University

Graduate School，Beijing University of Chinese Medicine

Guang 'anmen Hospital，China Academy of Chinese Medical Sciences

Department of Hepatology，Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

School of Traditional Chinese Medicine，Beijing University of Chinese Medicine

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰